Move a drug program forward
Compare candidates, doses and combinations across efficacy, safety, mechanism and biomarker readouts.
Explore relevant study options ↗PDO 2.0 · TUMOR & NORMAL ORGANOIDS · DISEASE MODELS
Human models for efficacy, safety and immune-context research.
TRiCBIO helps biopharma, CRO and research teams connect efficacy, safety, mechanism and immune-response studies in human organoid models. PDO 2.0 / ALI brings source-tissue architecture and immune cells retained from the sample into the same study.
HUMAN ORGANOID RESEARCH PLATFORMImmune context & ADC · normal-tissue safety · disease models
- ORGANOID MORPHOLOGY：Human organoid bright-field morphology
- PDO 2.0 · TISSUE & IMMUNE CONTEXT：Histology, epithelial and immune markers in colorectal source tissue and PDO 2.0
- ANTIBODY & NANOBODY · SECTION DISTRIBUTION：Relative spatial distribution of labeled antibody and nanobody in organoid frozen sections
- HUMAN NORMAL KIDNEY ORGANOIDS：Whole-organoid and local morphology of human normal kidney organoids
- NORMAL LUNG ORGANOIDS · AIRWAY LINEAGE：CC10 and KRT5 airway-lineage markers in normal lung organoids
- ADJACENT NON-TUMOR LIVER ORGANOIDS：Day 8 morphology of organoids from adjacent non-tumor liver tissue
- IBD · INFLAMMATION & BARRIER：Morphology and budding in a mouse intestinal organoid inflammation model
- BBB-RELATED CO-CULTURE · ZO-1 JUNCTIONS：ZO-1 junction imaging in a BBB-related co-culture system
- GBM PDO 2.0 · HISTOLOGY & LINEAGE：Histology and lineage markers in GBM tumor tissue and PDO 2.0
01HUMAN SAMPLES02MODELS & READOUTS03R&D DECISIONS
01PDO 2.0 / ALITissue architecture & immune cells retained from the source sample
02PEER-REVIEWED SCIENCEALI organoid research by TRiCBIO’s Chief Scientist was published in Nature Medicine, with tumor–immune organoid work published in Cell
03STUDY DESIGNModels and assays matched to your development objective
04Nanjing · Shanghai · PhiladelphiaChina R&D · global project coordination
Why TRiCBIO
Human organoid studies across efficacy, safety, mechanism and immune context
TRiCBIO designs organoid studies for efficacy, mechanism, tumor–immune biology and safety using PDO 2.0 / ALI, human tissue models and multimodal assays.
01ALI research · Nature Medicine · Cell
The science behind PDO 2.0 / ALI
From early ALI culture research in Nature Medicine to the 2018 Cell study of tumor–immune organoids, work involving TRiCBIO’s Chief Scientist continues to guide our PDO 2.0 platform and study design.
Explore PDO 2.0 02Model · assay · analysis · deliveryFrom model to R&D decision
Establish and characterize the model, then add efficacy, safety, mechanism and multimodal readouts to produce results and documentation your team can interpret and use.
Explore the technology 03Selected models · documented assays · flexible collaborationTumor, normal-tissue and disease models
Combine tumor PDOs, normal-tissue organoids and disease models to evaluate efficacy, mechanism and organ-specific safety within a connected research program.
Browse models 04Scientific team involvementBiopharma perspective, flexible engagement
Scientists with experience in target discovery, functional genomics, clinical pharmacology and drug development contribute to model and study design across contract research, model and product supply, custom development and scientific collaboration.
Meet the scientific teamWhat are you working on?
Match the model and study to your objective
Whether you are evaluating a candidate, developing a disease model or planning a collaborative study, we match the goal, sample context and available information to suitable model and study options.
Disease models & scientific collaboration
Develop clinical-sample organoids and disease models for functional validation, method development and collaborative research.
Explore relevant study options ↗Explore study options
Start with your study goal
Enter by study goal, therapeutic modality or model system, then continue to the relevant services, models and case studies.
Start with the question your team needs to answer
Begin with the question your team needs to answer, then explore the relevant services, models and evidence.
01
Target & mechanism
Test whether target modulation changes the relevant phenotype and pathway.
Explore the study approach 02Candidate comparison
Compare efficacy, dose, combinations and response differences across models.
Explore the study approach 03Safety & toxicology
Build a safety study around organ injury and exposure conditions.
Explore the study approach 04Immune microenvironment
Relate tissue context and immune components to treatment response.
Explore the study approachHow does the candidate work?
Different modalities call for different models, controls and readouts.
01
Small molecules & targeted agents
Compare dose, timing, combinations and mechanism-focused endpoints.
Explore the application 02Antibodies, multispecifics & TCEs
Examine target expression, effector context and dynamic killing together.
Explore the application 03ADCs
Study target heterogeneity, tissue spatial distribution and cytotoxicity.
Explore the application 04Immunotherapy
Combine PDO 2.0 / ALI with program-relevant immune readouts.
Explore the applicationChoose the biological context your study needs
Start with tumor, normal-tissue or disease models, then connect the right model and assays to the next stage of your program.
01
Tumor PDO & PDO 2.0
Choose by cancer, tissue context and need for immune information.
Browse relevant models 02Non-tumor organ models
Normal-tissue, adjacent non-tumor and stem-cell-derived models for tissue phenotypes, injury and organ-specific safety.
Browse relevant models 03Disease models
Study inflammation, barrier, cyst and disease-associated phenotypes.
Browse relevant models 04Custom & co-development
Develop specialized models, co-cultures and functional assays around the study goal.
Explore custom collaborationPDO 2.0 / ALI
Study the tumor together with its tissue context
PDO 2.0 uses an air–liquid interface to study treatment response alongside source-tissue architecture and immune cells retained from the original sample. It supports tumor-microenvironment profiling, immunotherapy and combination studies.
See how PDO 2.0 works01Tissue architecture and tumor-cell profilingH&E · IF · IHC
02Sample-derived immune-context profilingFACS · TCR · Cytokines
03Integrated histology, flow and functional analysisViability · Barrier · Response
Featured models & study results
Choose models for immune, efficacy and safety questions
Start with PDO 2.0 immune studies, normal-tissue safety or disease models, with linked case studies and assay readouts. The full directory includes additional tumor, normal-tissue, disease and custom models.
01
Featured model optionsChoose by model type and study context
Swipe or use arrow keys to explore more models
Tumor PDO 2.0
An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.
Model details & recommended uses ↗
Human kidney organoids
Assess drug-related kidney injury using morphology, nephron markers and molecular readouts; the culture approach is selected by compound mechanism and priority endpoint.
Model details & recommended uses ↗
IBD inflammation and barrier organoid model
For inflammatory bowel disease (IBD), established inflammation and barrier assays in mouse intestinal organoids support candidate comparison across morphology, permeability, viability and F-actin/ZO-1; we tailor a human study to the sample and program goal.
Model details & recommended uses ↗02
Study resultsExplore model characterization, readouts and study findings
Swipe or use arrow keys to explore more study results
PDO 2.0 tumor–immune response
Select histology, cell-death and T-cell profiling endpoints for immunotherapy studies across different sample contexts.
View study results ↗
ADC distribution & response in breast PDOs
Plan ADC imaging, dose selection and candidate comparisons using labeled-antibody/nanobody distribution and ADC activity readouts.
View study results ↗
Normal lung and kidney evidence for safety studies
Select a lung, kidney or dual-organ strategy with safety endpoints matched to the candidate's risk profile.
View study results ↗More models and custom studies
Explore the full portfolio or discuss a custom study
Tumor PDO / PDO 2.0Normal kidney · lung · stomach + adjacent non-tumor liverIBD inflammation & barrier methods · tailored ADPKD/BBB studiesMulti-organ safetySpecialized tissue & co-culture studies
Apply these capabilities to your study
Match models and assays ↗Share the candidate mechanism, priority endpoint and available sample; we will outline a recommended model, first-pass assay set and expected deliverables.
How we work
Four steps to project delivery
We clarify the project goal, select the model and assays, prepare the study plan and quotation, then run the study and interpret the results. The first discussion can start with the candidate and information already available.
Project goal
Clarify the objective and priority endpoints
Plan and quote
Confirm the model, assays and study scope
Study and analysis
Run the study and integrate the data
Results and next step
Review the results and agree on the next study step
Project inquiry
Discuss your organoid study
After the first discussion, we’ll recommend an initial model and assay approach, then define the study scope, timeline, deliverables and quote.